SAN FRANCISCO, Feb. 4 /PRNewswire-FirstCall/ – Medizone
International, Inc. (OTC Bulletin Board: MZEI) announced today that
every full scale test run completed thus far in its hospital room
mock up facility has resulted in the total elimination of all bacteria
present in the room. In this current phase of development, Medizone’s
scientific team will attempt to confirm, in a more realistic hospital
setting, recent laboratory findings indicating extremely high
antibacterial efficacy for its novel technology (6-7.2 log reductions)
against the primary causative agents of hospital acquired infections
(HAIs), sometimes referred to as “Super Bugs”.   Dr. Michael Shannon,
Medizone’s Director of Medical Affairs commented, “From the very onset,
our new scaled up sterilization system performed magnificently.  We
have now completed multiple runs with very high concentrations of
MRSA, VRE and E. coli samples that were distributed
throughout the test room. In every instance, the AsepticSure™ system
produced greater than 6 log (99.9999%) reductions, which by definition, is
sterilization. It is noteworthy in this regard that there was absolutely
no growth on any of the artificially contaminated surfaces exposed to the
AsepticSure™ process.” Shannon continued, “Our intention now is to
systematically collect empirically verifiable scientific data on all the
remaining causative agents of HAIs.  Given these recent results
in a full room test setting which precisely mirrors our laboratory set up,
we fully expect the same results with all remaining bacteria as well as
Bacillus subtilis, the recognized surrogate for Anthrax. Thus,
while more testing and data acquisition must be completed before moving
into hospital beta testing, it now seems certain that AsepticSure™
will deliver as promised.”

Medizone’s CEO Edwin Marshall added, “One of our concerns from the
beginning has been the protection of the very expensive electronics found
throughout hospitals. We have been testing electronic devices exposed to
our process from the very beginning of our laboratory trials.  While
our electronic testing program will now be intensified to assure we are
not making false assumptions, it is encouraging to note that one highly
sensitive electronic instrument has now undergone over 50 exposures to our
protocol, many at much higher O3 concentrations than we are now using,
and it still performs as if it was brand new.”

Medizone International, Inc., is a research and development company
engaged in developing its AsepticSure™ System to decontaminate and
sterilize hospital surgical suites, emergency rooms, intensive care units,
schools and other critical infrastructure. A government variant is being
developed for bio-terrorism counter measures.  Current research is
being conducted at Medizone’s dedicated laboratories located in Innovation
Park, Queen’s University in Kingston, Ontario, Canada.

This Press Release contains certain forward looking statements that
involve substantial risks and uncertainties, including, but not limited
to, the results of ongoing clinical studies, economic conditions, product
and technology development, production efficiencies, product demand,
competitive products, competitive environment, successful testing and
government regulatory issues. Additional risks are identified in the
company’s filings made with the Securities and Exchange Commission.

Investor Relations: 415-868-0300 / web site: href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=657&L=1282&F=H">www.medizoneint.com

E-mail: href="mailto:operations@medizoneint.com;_ylt=AoOXl9eJwvaRWs24.QqJ1xuxcq9_;_ylu=X3oDMTE2dWZoYXQxBHBvcwMyBHNlYwNuZXdzYXJ0Ym9keQRzbGsDb3BlcmF0aW9uc21l">operations@medizoneint.com